Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice. Research peptides discussed are not FDA-approved for human use. Always consult a licensed healthcare professional. See our full disclaimer.
Quick Answer: BPC-157, TB-500, and GHK-Cu are the three most widely used healing peptides, each targeting a different step of tissue repair. BPC-157 stimulates growth factors (VEGF, EGF, FGF) and excels at tendon, ligament, and gut healing. TB-500 (a TB-4 fragment) drives cell migration, angiogenesis, and broad systemic tissue remodeling — favored for major soft-tissue injury. GHK-Cu is a copper-binding tripeptide that activates collagen synthesis, wound healing, and follicular regeneration — used topically for skin and hair or by injection for deeper tissue support. The three peptides have complementary mechanisms and are frequently stacked as the 'Wolverine Plus' protocol for maximal healing effect.
At a Glance
| Peptide | Length | Primary Target | Route | Strongest Use Case |
|---|---|---|---|---|
| BPC-157 | 15 aa | Growth factor upregulation | SC injection or oral | Tendon, ligament, gut |
| TB-500 (Tβ4 fragment) | 4 aa fragment | Actin remodeling, cell migration | SC injection | Soft tissue, systemic healing |
| GHK-Cu | 3 aa + Cu²⁺ | Collagen, wound, follicle | Topical, SC, IV | Skin, hair, wound repair |
Mechanisms in Detail
BPC-157
BPC-157 upregulates VEGF, EGF, and FGF, activates FAK-paxillin signaling, and modulates the nitric oxide system. Those mechanisms translate into enhanced angiogenesis, cell proliferation, and tissue remodeling. It's particularly effective at tendon/ligament injury because collagen-producing cells respond strongly to its growth factor signals.
TB-500
TB-500 is a synthetic fragment mimicking thymosin-β4's actin-binding region. Actin remodeling is foundational to cell migration — for tissue healing, that means new cells efficiently move into damaged areas. TB-500 also upregulates hepatocyte growth factor (HGF) and IGF-1. Because of its strong systemic distribution, it produces broader tissue effects than BPC-157.
GHK-Cu
GHK-Cu is a copper-carrier tripeptide that activates wound healing pathways: collagen synthesis, elastin production, fibroblast migration, and anti-inflammatory signaling. Topical applications are documented for skin and hair; systemic use extends these effects to internal wound healing and cardiovascular support.
Ideal Use Cases
BPC-157 Excels At
- Tendon and ligament injuries (Achilles, ACL, rotator cuff)
- Gut barrier and IBD-type conditions
- Mild joint injuries and cartilage stress
- Post-surgery recovery
- Localized tissue healing where focal growth factor support is beneficial
TB-500 Excels At
- Major soft tissue injuries (muscle tears, significant strains)
- Systemic inflammation and broad tissue recovery
- Cardiac tissue support (cardiomyocyte protection in research)
- Post-overtraining recovery in athletes
- Vascular and endothelial repair
GHK-Cu Excels At
- Skin anti-aging and wound healing (topical)
- Hair growth and follicular support (topical and systemic)
- Cosmetic recovery (post-laser, post-procedure)
- Mature skin collagen remodeling
- Cardiac and vascular remodeling (systemic, in research)
Dosing Protocols
| Peptide | Typical Dose | Frequency | Route | Duration |
|---|---|---|---|---|
| BPC-157 | 200–500 mcg | 1× daily | SC | 8–12 weeks |
| BPC-157 (oral) | 500–1000 mcg | 1–2× daily | Oral | 8–12 weeks |
| TB-500 (loading) | 2–5 mg | 1–2× weekly | SC | 4–6 weeks |
| TB-500 (maintenance) | 2 mg | Every 1–2 weeks | SC | Ongoing |
| GHK-Cu topical | 0.05–0.2% serum | 1–2× daily | Topical | 12+ weeks |
| GHK-Cu injectable | 1–3 mg | 2–3× weekly | SC | 6–12 weeks |
Stacking: The Wolverine Plus
The most common healing stack combines all three peptides: the Wolverine Plus protocol. A representative version:
- BPC-157: 250 mcg subcutaneous once daily
- TB-500: 2 mg subcutaneous once weekly (loading 2× weekly for first 4 weeks)
- GHK-Cu: 2 mg subcutaneous 2× weekly OR topical 0.2% serum daily
- Duration: 8–12 weeks
- Complementary: Pair with physical therapy, adequate protein, and sleep optimization
Reports from serious-injury recovery (ACL, large soft tissue tears, surgical recovery) are the strongest anecdotal support for this stack. Dose adjustment based on injury severity and individual response is standard.
Safety Profiles
All three peptides have favorable safety profiles in animal studies and anecdotal human use. Injection site reactions, mild headaches, occasional nausea, and fatigue are the most commonly reported side effects across the group.
Theoretical concerns are similar: all three peptides stimulate growth factors and angiogenesis, which could theoretically support tumor growth in susceptible individuals. People with personal or family cancer histories should consult medical professionals before use.
Long-term human data beyond 12 weeks are lacking for all three. Periodic breaks (4-week washout every 8–12 weeks) are standard precautionary practice.
Evidence Comparison
- BPC-157: 30+ years of animal research; limited human data; evidence tier B for injury, tier B for gut
- TB-500: Animal research across multiple injury models; human data very limited; evidence tier B for major injury
- GHK-Cu: Large evidence base for topical skin/hair; growing injectable evidence; evidence tier B overall, tier A for topical cosmetic use
None of the three has robust randomized clinical trials for injury recovery in humans, though cosmetic GHK-Cu formulations have significant RCT evidence.
Cost Considerations
A rough monthly cost comparison at typical biohacking doses:
- BPC-157: ~$50–80/month at 250 mcg daily
- TB-500: ~$80–130/month at 2 mg weekly
- GHK-Cu topical: ~$30–60/month for quality serum
- GHK-Cu injectable: ~$60–90/month
- Full Wolverine Plus stack: ~$200–300/month
Cost varies widely by vendor, purity, and dosing. Start conservatively and titrate based on response.
Bottom Line
These three peptides aren't alternatives — they're complementary. BPC-157 is the default starting point for tendon, ligament, or gut issues. TB-500 adds systemic tissue support for major injuries. GHK-Cu provides collagen and skin/hair benefits plus additional wound healing effects. Together they form the Wolverine Plus stack, a go-to regimen for serious injury recovery. Individually, matching the right peptide to the right injury is key. For most users, starting with one peptide (typically BPC-157), assessing response, and layering in TB-500 or GHK-Cu based on goals is the most practical approach.
Recommended Research Vendors
For researchers sourcing compounds discussed in this article, the following vendors maintain third-party purity testing, transparent sourcing, and established reputations in the research peptide community. WolveStack earns a small commission on referred purchases, which funds our research and writing work — this does not affect our editorial evaluation of each vendor.
🧪 Ascension Research
Third-party tested research peptides. Transparent COAs, reliable sourcing, and fast shipping make Ascension a top choice for researchers.
Visit Ascension →🧬 Particle Peptides
Pharma-grade purity with full HPLC/MS certificates for every batch. Particle is known for clinical-grade quality and precision research protocols.
Visit Particle →💎 Limitless Life
Popular for novel and hard-to-source research compounds. Limitless offers a broad catalog of frontier peptides backed by third-party testing.
Visit Limitless →Frequently Asked Questions
They target different phases of healing, so 'faster' depends on injury type. BPC-157 often produces faster symptomatic relief for tendon/ligament issues and gut problems, while TB-500 tends to produce more comprehensive systemic recovery for major soft-tissue injuries. For severe cases, combining both is typically superior to either alone.
GHK-Cu has both cosmetic and systemic healing applications. Topical GHK-Cu is well-validated for skin regeneration and hair growth. Injectable GHK-Cu extends these effects to broader wound healing, cardiovascular support, and deep tissue repair, though human injectable evidence is smaller than topical evidence.
Yes, this is called the Wolverine Plus protocol. Combined use is common for serious injury recovery and post-surgery rehabilitation. Typical combination: BPC-157 daily, TB-500 weekly, GHK-Cu topical daily or injectable twice weekly. All three have compatible mechanisms and safety profiles.
All three are sold as research chemicals in most jurisdictions — legal to purchase for research purposes but not FDA-approved for human use. Specific regulations vary by country. Always verify local laws before sourcing.
In the US, research peptides can be purchased from licensed research suppliers without prescription, labeled 'not for human use.' Prescription-grade versions from compounding pharmacies require prescriptions. Other countries have different regulations.
BPC-157 is typically recommended as the starting point because of its broad applications, easier oral bioavailability, and 30+ year research history. Assess your response at 6–8 weeks, then decide whether to add TB-500 or GHK-Cu based on goals. For skin and hair specifically, GHK-Cu topical is the better starting point.
Standard protocol: 8–12 weeks on, 4 weeks off. This mirrors animal research and allows physiologic recovery between cycles. Some users cycle continuously at lower maintenance doses; others cycle for specific injuries and stop once healing is complete.
Yes, the two peptides are compatible and can be mixed in a single subcutaneous injection without loss of efficacy. Many users combine them to reduce daily injection count. GHK-Cu injectable is sometimes added as a third component but is more commonly dosed separately.
You Might Also Like
About the Author
The WolveStack research team compiles peer-reviewed scientific literature, clinical trial data, and accumulated biohacking community experience to deliver evidence-first peptide education. Our guides reflect the current state of research and common practices in the researcher community, with emphasis on critical evaluation and transparent discussion of what is and isn't known.